Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$185.8 million.

  • Enanta Pharmaceuticals' Enterprise Value rose 1423.32% to -$185.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$185.8 million, marking a year-over-year increase of 1423.32%. This contributed to the annual value of -$188.9 million for FY2025, which is 2390.22% up from last year.
  • As of Q4 2025, Enanta Pharmaceuticals' Enterprise Value stood at -$185.8 million, which was up 1423.32% from -$188.9 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' 5-year Enterprise Value high stood at -$185.8 million for Q4 2025, and its period low was -$386.6 million during Q2 2023.
  • For the 5-year period, Enanta Pharmaceuticals' Enterprise Value averaged around -$260.2 million, with its median value being -$248.7 million (2022).
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Enterprise Value plummeted by 5720.19% in 2023, and later surged by 4048.27% in 2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Enterprise Value (Quarter) stood at -$259.1 million in 2021, then grew by 17.21% to -$214.5 million in 2022, then tumbled by 57.2% to -$337.2 million in 2023, then skyrocketed by 35.73% to -$216.7 million in 2024, then increased by 14.23% to -$185.8 million in 2025.
  • Its Enterprise Value stands at -$185.8 million for Q4 2025, versus -$188.9 million for Q3 2025 and -$204.1 million for Q2 2025.